Delving into the Latest Updates on Chengdu Olymvax Biopharmaceuticals, Inc. with Synapse

Overview

Tags

Infectious Diseases

Respiratory Diseases

Nervous System Diseases

Prophylactic vaccine

Conjugated vaccine

Multivalent vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	18
Neoplasms	2
Nervous System Diseases	1

Top 5 Drug Type	Count

Prophylactic vaccine	15
Conjugated vaccine	5
Multivalent vaccine	4
Monoclonal antibody	2
Synthetic peptide	1

Top 5 Target	Count

alpha-toxin(Alpha-hemolysin)	2
Varicella-zoster virus gH/gL	1
IL-2(Interleukin-2)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

8

Preclinical

IND Approval

1

2

Phase 1

Phase 2

1

Phase 3

Approved

3

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Hib conjugate vaccine(Chengdu Olymvax Biopharmaceuticals, Inc.)	Haemophilus Infections More	Approved
A/C meningococcal conjugate vaccine(Olymvax Biopharmaceuticals)	Meningitis More	Approved
Tetanus Vaccine,Adsorbed(Chengdu Olymvax Biopharmaceuticals, Inc.)	Tetanus More	Approved
Recombinant Staphylococcus Aureus(Escherichia Coli)(Chongqing Yuanlun Biotechnology)	Staphylococcal Infections More	Phase 3
Recombinant Staphylococcus Aureus(Chengdu Olymvax Biopharmaceuticals, Inc.)	Staphylococcus Aureus Infections More	Phase 2